- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02887989
Immersive Virtual Reality Intervention for Non-Opioid Pain Management: A Randomized Controlled Trial
15. november 2018 oppdatert av: Brennan Spiegel, Cedars-Sinai Medical Center
The study is a randomized controlled trial (RCT) of VR non-opioid management vs. a control "sham" intervention for a broad and representative group of medical and surgical patients with pain.
Hospitalized patients will receive specialized VR interventions, administered via portable VR headsets, to manage breakthrough pain.
Control patients will view content on the in-room Health and Wellness television channel.
Investigators will follow patients throughout the course of their hospitalization and monitor outcomes during and after their stays, including pain levels, medication requests, and quality of life.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The study population will consist of 120 patients - 60 patients who are exposed to VR, and 60 control patients exposed to an audiovisual "sham" intervention.
Investigators will select up to 120 hospitalized patients at CSMC admitted during the study period of November 2016 to September 2017.
The inpatient wards serve patients ranging in age from 18 to over 100, allowing us to assess the feasibility of using VR across diverse age groups.
Appropriate inpatients will be selected at random by Dr. Rosen or other authorized co-investigators or study staff, who will obtain relevant clinical variables from the EHR.
All patients admitted to the hospital will be considered for the study.
The location and identity of the inpatient will be relayed by their attending physician to a member of the study team, who will deliver a randomly selected intervention (either VR or Health and Wellness Channel) to the patient the same day (at the patient's discretion).
The patient will continue usage as needed for up to 20 days of the hospital stay.
VR Interventions include both relaxing environment and engaging games.
The Health and Wellness Channel includes some of the same types of content, but it is delivered passively through the in-room television system.
Investigators will examine changes in pain level, length of stay, medication requests (amount and timing), Quality of Life, Functioning, and Patient Satisfaction.
Studietype
Intervensjonell
Registrering (Faktiske)
140
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90048
- Cedars-Sinai Medical Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 110 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Able to understand the goals of the study and provide informed consent
- Any hospitalized patient under care of CSMC inpatient service (ISP), gastroenterology, or psychiatry, admitted between November 2016 and 30 September 2017, who is not excluded due to criteria listed below.
- At least one pain score ≥ 3 documented in the EHR.
- Received at least three doses of opioid medication for breakthrough pain, documented in the EHR.
- At least 18 years of age
- English speaking
Exclusion Criteria:
- Unable to consent to study due to cognitive difficulty
- Contact Isolation
- Current diagnosis of epilepsy, dementia, or other neurological disease that may prevent use of VR hardware and software
- Sensitivity to flashing light or motion
- Pregnancy, or a medical condition where the patient is prone to frequent nausea or dizziness
- Recent stroke
- Post-transplant patient, or pre-transplant patient with severe illness
- Patient on ventilator, BiPAP, or other breathing assistance equipment
- Injury to the eyes, face, neck, or arms that prevents comfortable use of VR hardware or software, or safe use of the hardware (e.g., open sores, wounds, or skin rash on face)
- Non-English speaking
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Virtual Reality
Patients will be allowed to use commercially-available VR equipment in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
|
A menu of VR experiences, lasting from 3-30 minutes each.
For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
|
|
Sham-komparator: 'Health and Wellness Channel'
Patients will be allowed to watch relaxing television content in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
|
Relaxing content broadcast passively on the patient in-room television channel.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Intensity Ratings (NRS)
Tidsramme: Approximately every 3-4 hours for the period 48 hours pre and post intervention
|
The primary outcome was pain intensity collected via ecological momentary assessment in the course of usual care by hospital staff.
At three-to-four hour intervals during waking hours, subjects were asked by their assigned nurse to rate their pain using a standard 11-point numeric rating scale (NRS), where 0 is "no pain" and 10 is "worst imaginable pain."
Data are summarized as pre/post mean and in time-series.
|
Approximately every 3-4 hours for the period 48 hours pre and post intervention
|
|
Morphine Milligram Equivalents (MME)
Tidsramme: assessed at 48 hours before intervention and 48 hours after intervention
|
Opioid usage was defined as mean total milligrams of morphine equivalent (MME), calculated by first multiplying the quantity of each prescribed medication by the strength of that medication (milligrams of given opioid per unit dispensed), and then multiplying this quantity-strength product by conversion factors derived from published sources to estimate the milligrams of morphine equivalent to the opioids dispensed in the prescription.
The mean pre-intervention MME for subjects in each arm was calculated by adding the morphine equivalents for each prescription dispensed during the 48 hours before intervention, while the post-intervention MME for subjects in each arm was calculated by adding the morphine equivalents for each prescription dispensed during the 48 hours after intervention.
|
assessed at 48 hours before intervention and 48 hours after intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Length of Stay) LOS
Tidsramme: Count of Days in Hospital Stay up to 20
|
defined as the number of days from the date of admission to date of hospital discharge.
Hour of admission was not available in these data, so patients admitted late on Day 0 (i.e., before midnight), and discharged the following calendar day (i.e., between 00:00 and 23:59), were counted as a 1-day hospital stay.
Patients who were admitted and discharged on the same calendar day were considered to have an LOS of 0.
|
Count of Days in Hospital Stay up to 20
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Brennan Spiegel, MD, MSHS, Cedars-Sinai Medical Center
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
16. november 2016
Primær fullføring (Faktiske)
17. juli 2017
Studiet fullført (Faktiske)
17. august 2017
Datoer for studieregistrering
Først innsendt
30. august 2016
Først innsendt som oppfylte QC-kriteriene
1. september 2016
Først lagt ut (Anslag)
2. september 2016
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
20. november 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
15. november 2018
Sist bekreftet
1. november 2018
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- Pro00045641
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .